



iTrack™ Canaloplasty to be Featured at the 2025 European Society of Cataract and Refractive Surgeons (ESCRS) Annual Congress

California, USA, August 12, 2025 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary canaloplasty technology platform (*iTrack™* and *iTrack™ Advance*) will be featured in numerous presentations and posters during the official scientific program of the European Society of Cataract and Refractive Surgeons (ESCRS) 43rd Congress, September 12-16, 2025 in Copenhagen, Denmark.

A summary of the ESCRS 2025 presentations and posters featuring iTrack™ and iTrack™ Advance is included below.

Podium Presentations:

Shamil Patel, MD, MBA (USA)

Canaloplasty Effectiveness Correlated with Viscoelastic Volume Delivered in Schlemm's Canal

Sunday, 14 September 14:10-14:15 | Free paper podium 4

Session: Advances in Glaucoma Surgery

Norbert Koerber, MD, FEBO (Germany) and Simon Ondrejka, MD (Germany)

10-year Effectiveness and Safety outcomes of Ab-interno Canaloplasty in Open-angle Glaucoma

Sunday, 14 September 14:15-14:20 | Free paper podium 4

Session: Advances in Glaucoma Surgery

Simon Ondrejka, MD (Germany) and Norbert Koerber MD, FEBO (Germany)

Safety and Efficacy of Ab-interno Canaloplasty with Using the iTrack Advance in Open-Angle Glaucoma – 2-Year Results

Sunday, 14 September 15:20-15:25 | Free paper podium 4

Session: Advances in Glaucoma Surgery

Shamil Patel, MD, MBA (USA)

Results of iTrack Global Data Registry to Support the Role of Canaloplasty for Treatment of Glaucoma

Monday, 15 Sep | 14:10-14:15 | Free paper podium 2



Session: Contemporary Surgical Interventions in Glaucoma

Posters:

James Murphy, MD (USA)

Efficacy and Safety of Ab-Interno Canaloplasty with and without GATT in Glaucoma: 5-Year Outcomes

Session: Minimally Invasive Glaucoma Surgery (MIGS)

Keith Barton, MD, FRCP, FRCS (UK)

Multicenter Canaloplasty Data Registry – Outcomes of Ab-Interno Canaloplasty Across Different Glaucoma Types and Severities

Session: Minimally Invasive Glaucoma Surgery (MIGS)

Mary Qiu, MD (USA), Samantha Goldberg, MD (USA)

Clinical Outcomes and Safety Profile of Standalone Canaloplasty vs. Canaloplasty Combined with Cataract Surgery Using iTrack Microcatheter

Presented poster Pod 2: Sunday, 14 September from 17:05

Session: Combined glaucoma / cataract surgery

Karl Mercieca, MD, PGCME, FRCOphth, FEBOS-GL (Germany)

Canaloplasty performed with the iTrack microcatheter to Reduce IOP in Uncontrolled Glaucoma Eyes

Presented poster Pod 3: Monday, 15 Sep from 15:20

Session: Minimally Invasive Glaucoma Surgery (MIGS)

Full session details can be accessed via the [ESCRS program](#).

All educational content of the ESCRS Annual Meeting is planned by its Program Committee. The ESCRS do not endorse, promote, approve, or recommend the use of any products, devices, or services.



ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

The iTrack™ Advance canaloplasty device has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

Indications for Use, US: The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.*

The ab interno surgical technique is not a cleared indication for the iTrack™ Advance in the USA.

* The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.

Indications for Use, International: The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

For additional information about the iTrack™ Advance, including safety information, please visit: <https://itrack-advance.com>



For media enquiries, please contact:

Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com

Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu